Yttrium-90 ibritumomab tiuxetan with high-dose carmustine, cytarabine, etoposide, and melphalan (Zevalin-BEAM) conditioning regimen in relapsed aggressive non-Hodgkin lymphoma

被引：0
|
作者：
Tan, S. M. [1 ]
Lau, N. S. [1 ]
Lim, S. M. [1 ]
Zanapiah, M. [1 ]
Chang, K. M. [1 ]
机构：
[1] Hosp Ampang, Ampang, Myanmar
来源：
BONE MARROW TRANSPLANTATION | 2008年 / 41卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S440 / S441
页数：2
相关论文
共 50 条
  • [1] Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology
    Krishnan, Amrita Y.
    Palmer, Joycelynne
    Nademanee, Auayporn R.
    Chen, Robert
    Popplewell, Leslie L.
    Tsai, Ni-Chun
    Sanchez, James F.
    Simpson, Jennifer
    Spielberger, Ricardo
    Yamauchi, Dave
    Forman, Stephen J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (06) : 922 - 929
  • [2] Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?
    Krishnan, Amrita Y.
    Palmer, Joycelynne
    Nademanee, Auayporn P.
    Chen, Robert
    Popplewell, Leslie L.
    Tsai, Nicole
    Sanchez, James F.
    Simpson, Jennifer
    Spielberger, Ricardo
    Yamauchi, Dave
    Forman, Stephen J.
    BLOOD, 2015, 126 (23)
  • [3] Yttrium-90 -: ibritumomab tiuxetan (Zevalin®) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin lymphoma
    Shimoni, A.
    Zwas, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Avigdor, A.
    Ben-Bassat, I.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S145 - S145
  • [4] Autologous Transplantation for Transformed Non-Hodgkin Lymphoma Using an Yttrium-90 Ibritumomab Tiuxetan Conditioning Regimen
    Mei, Matthew
    Wondergem, Marielle J.
    Palmer, Joycelynne M.
    Shimoni, Avichai
    Hasenkamp, Justin
    Tsai, Ni-Chun
    Simpson, Jennifer
    Nademanee, Auayporn
    Raubitschek, Andrew
    Forman, Stephen J.
    Krishnan, Amrita Y.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (12) : 2072 - 2075
  • [5] Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
    McKinney, Matthew S.
    Beaven, Anne W.
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2014, 4 : 45 - 59
  • [6] Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma
    Krishnan, Amrita
    Nademanee, Auayporn
    Fung, Henry C.
    Raubitschek, Andrew A.
    Molina, Arturo
    Yamauchi, Dave
    Rodriguez, Roberto
    Spielberger, Ricardo T.
    Falk, Peter
    Palmer, Joycelynne M.
    Forman, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) : 90 - 95
  • [7] Comparison between BEAM and Yttrium-90 Ibritumomab Tiuxetan (Zevalin)-BEAM as conditioning regimen before autologous stem cell transplantation in patients with non-Hodgkin B-Cell Lymphoma
    Chic Acevedo, C.
    Garcia Torres, E.
    Llamas Poyato, M. J.
    Rodriguez, G.
    Martin, C.
    Rojas, R.
    Serrano, J.
    Tabares, S.
    Vallejo, J. A.
    Sanchez, J.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S224 - S224
  • [8] Efficacy and safety of yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
    Doyle, Catherine
    Smith, Johnna
    Bello, Celeste M.
    Sokol, Lubomir
    El-Haddad, Ghassan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [9] A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma
    Shimoni, Avichai
    Avivi, Irit
    Rowe, Jacob M.
    Yeshurun, Moshe
    Levi, Itai
    Or, Reuven
    Patachenko, Paulina
    Avigdor, Abraham
    Zwas, Tzila
    Nagler, Arnon
    CANCER, 2012, 118 (19) : 4706 - 4714
  • [10] The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
    Cheson, BD
    BIODRUGS, 2005, 19 (05) : 309 - 322
12345